KMDA
KAMADA LTD
$7.44
0.00%
$429.2M
No data for this timeframe.
Vol
Market Cap$429.2M
Cap SizeSmall Cap
SEC Reports4
Press Releases3
Recent Activity
Jun 1, 2026
SEC
Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufa
6-K — Impact 5/10
Jun 1, 2026
fda
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
<p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Lt
May 13, 2026
SEC
Kamada reported Q1 2026 EPS of $0.06, a 47.8% miss vs the $0.12 consensus, and revenue of $45.2M (+3% YoY) which was wel
PRESS-RELEASE — Impact 7/10
Apr 7, 2026
Insider
Payorski Lilach was granted 7,500 shares
Director
Apr 7, 2026
Insider
Payorski Lilach disposed of 7,500 shares
Director
Apr 7, 2026
Insider
Brenner Yael was granted 15,000 shares
VP Quality
Mar 31, 2026
SEC
Kamada Ltd. announced a tax ruling from the Israel Tax Authority that allows eligible Nasdaq-listed shareholders to bene
6-K — Impact 3/10
Mar 26, 2026
Press
Kamada Ltd. announced FDA approval for its San Antonio plasma collection center, enabling commercial sales of normal sou
Impact 7/10
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$13.00 (Dec 2025)
Current $7.44
Low $11.00
Median $13.00
High $15.00
4 analysts
$11.00
$15.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 9, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 15, 2025 | Benchmark | REITERATE | Buy → Buy |
| Mar 21, 2025 | Benchmark | INITIATE | Buy |
| Mar 6, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 10, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.11 ▼ -6.2% | $0.09 — $0.13 | -13% YoY | 4 |
| Next Q | $0.13 ▼ -5.7% | $0.12 — $0.13 | 39% YoY | 4 |
| Current FY | $0.43 ▼ -15.3% | $0.40 — $0.47 | 22% YoY | 4 |
| Next FY | $0.61 ▲ +3.4% | $0.52 — $0.68 | 43% YoY | 3 |
Latest Reports
BULLISH
6-K
5/10
Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufa
Jun 1, 2026
BEARISH
PRESS-RELEASE
7/10
Kamada reported Q1 2026 EPS of $0.06, a 47.8% miss vs the $0.12 consensus, and revenue of $45.2M (+3% YoY) which was wel
May 13, 2026
BULLISH
Press
7/10
Kamada Ltd. announced FDA approval for its San Antonio plasma collection center, enabling commercial sales of normal sou
Mar 26, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 7, 2026 | Payorski Lilach | A | $0.00 |
| Apr 7, 2026 | Payorski Lilach | D | $0.00 |
| Apr 7, 2026 | Brenner Yael | A | $0.00 |
| Apr 7, 2026 | Nir Eran | A | $0.00 |
| Apr 7, 2026 | Beladev Shavit | D | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
17 unique insiders with 34 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 7, 2026 | Payorski Lilach | Director | AWARD | 7,500 | — | — |
| Apr 7, 2026 | Payorski Lilach | Director | D | 7,500 | — | — |
| Apr 7, 2026 | Brenner Yael | VP Quality | AWARD | 15,000 | — | — |
| Apr 7, 2026 | Nir Eran | VP, Operations | AWARD | 22,500 | — | — |
| Apr 7, 2026 | Beladev Shavit | VP Plasma Operations | D | 15,000 | — | — |
| Apr 7, 2026 | Brenner Yael | VP Quality | D | 15,000 | — | — |
| Apr 7, 2026 | Nir Eran | VP, Operations | D | 22,500 | — | — |
| Apr 7, 2026 | Beladev Shavit | VP Plasma Operations | AWARD | 15,000 | — | — |
| Apr 7, 2026 | Tsur David | Director | AWARD | 6,625 | — | — |
| Apr 7, 2026 | Tsur David | Director | D | 6,625 | — | — |
| Apr 7, 2026 | Pinchuk Orit | VP Regulatory Affairs | AWARD | 15,000 | — | — |
| Apr 7, 2026 | Pinchuk Orit | VP Regulatory Affairs | D | 15,000 | — | — |
| Apr 7, 2026 | DAVIDI ISHAY | Director | AWARD | 6,625 | — | — |
| Apr 7, 2026 | DAVIDI ISHAY | Director | D | 6,625 | — | — |
| Apr 7, 2026 | ORLEV CHAIME | Chief Financial Officer | AWARD | 22,500 | — | — |
| Apr 7, 2026 | ORLEV CHAIME | Chief Financial Officer | D | 22,500 | — | — |
| Apr 7, 2026 | Livneh Nir | VP, General Counsel | AWARD | 9,485 | — | — |
| Apr 7, 2026 | RECANATI LEON | Director | AWARD | 6,625 | — | — |
| Apr 7, 2026 | Goldwasser Karnit | Director | D | 6,625 | — | — |
| Apr 7, 2026 | Livneh Nir | VP, General Counsel | D | 9,485 | — | — |
| Apr 7, 2026 | Dekel Benjamin | Director | AWARD | 4,000 | — | — |
| Apr 7, 2026 | Reshef Liron | VP Human Resources | D | 10,000 | — | — |
| Apr 7, 2026 | Dekel Benjamin | Director | D | 4,000 | — | — |
| Apr 7, 2026 | Goldwasser Karnit | Director | AWARD | 6,625 | — | — |
| Apr 7, 2026 | RECANATI LEON | Director | D | 6,625 | — | — |
| Apr 7, 2026 | ITSHAYEK ASSAF | Director | AWARD | 4,000 | — | — |
| Apr 7, 2026 | Neheman Hanni | VP, Marketing & Sales | AWARD | 15,000 | — | — |
| Apr 7, 2026 | ITSHAYEK ASSAF | Director | D | 4,000 | — | — |
| Apr 7, 2026 | Neheman Hanni | VP, Marketing & Sales | D | 15,000 | — | — |
| Apr 7, 2026 | London Amir | Chief Executive Officer | AWARD | 100,000 | — | — |
| Apr 7, 2026 | Reshef Liron | VP Human Resources | AWARD | 10,000 | — | — |
| Apr 7, 2026 | Gorelik Boris | VP, BD and Strategic Programs | AWARD | 3,750 | — | — |
| Apr 7, 2026 | Gorelik Boris | VP, BD and Strategic Programs | D | 3,750 | — | — |
| Apr 7, 2026 | London Amir | Chief Executive Officer | D | 100,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
BULLISH
6-K
5/10
Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which
Jun 1, 2026
BEARISH
PRESS-RELEASE
7/10
Kamada reported Q1 2026 EPS of $0.06, a 47.8% miss vs the $0.12 consensus, and revenue of $45.2M (+3
May 13, 2026
NEUTRAL
6-K
3/10
Kamada Ltd. announced a tax ruling from the Israel Tax Authority that allows eligible Nasdaq-listed
Mar 31, 2026
BULLISH
6-K
7/10
Kamada Ltd. announced FDA approval of its plasma collection center in San Antonio, Texas, enabling t
Mar 26, 2026
BULLISH
7/10
Kamada Ltd. announced FDA approval for its San Antonio plasma collection center, enabling commercial
Mar 26, 2026
BULLISH
8/10
Kamada Ltd. reported strong 2025 full-year results with revenue of $180.5 million (up 12% YoY), adju
Mar 11, 2026
NEUTRAL
4/10
Kamada Ltd. declared a cash dividend of $0.25 per share, totaling approximately $14.4 million, payab
Mar 11, 2026
Historical analyst distribution (last covering-analyst action Dec 2025): 89% buy across 9 analysts — 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$13.00 mean target (Dec 2025)
$11.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $7.44 |
| Target Low | $11.00 |
| Target Mean | $13.00 |
| Target Median | $13.00 |
| Target High | $15.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.11 | $0.09 | $0.13 | -13.5% | -6.2% | 2↑ 2↓ | $0.1B | -3.9% | 4 |
| Next Q 2026-09-30 |
$0.13 | $0.12 | $0.13 | 38.9% | -5.7% | 1↑ 1↓ | $0.2B | 1.9% | 4 |
| Current FY 2026-12-31 |
$0.43 | $0.40 | $0.47 | 22.1% | -15.3% | 0↑ 4↓ | $0.6B | 5.2% | 4 |
| Next FY 2027-12-31 |
$0.61 | $0.52 | $0.68 | 43.5% | +3.4% | 1↑ 0↓ | $0.6B | 9.8% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.113 | |
| 7d ago | $0.113 | |
| 30d ago | $0.120 | -0.007 |
| 60d ago | $0.120 | -0.007 |
| 90d ago | $0.117 | -0.004 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 9, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 15, 2025 | Benchmark | REITERATE | Buy | Buy |
| Mar 21, 2025 | Benchmark | INITIATE | — | Buy |
| Mar 6, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 3, 2024 | Stifel | INITIATE | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 14, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 17, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 25, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 16, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Feb 2, 2018 | Chardan Capital | INITIATE | — | Buy |
| Nov 13, 2015 | Jefferies | MAINTAIN | — | Buy |
| Jun 25, 2013 | Jefferies | INITIATE | — | Buy |
| Jun 25, 2013 | Morgan Stanley | INITIATE | — | Equal-Weight |
| Jun 25, 2013 | Oppenheimer | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
fda
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
<p align="justify">REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biophar
May 13, 2026
earnings
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
<p align="justify">REHOVOT, Israel, and HOBOKEN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharm
May 13, 2026
earnings_calendar
KMDA Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
earnings
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to Host Conference Call at 8:30am ET <pre>Company to Host Conference Call at 8:30am ET</pre>
Mar 26, 2026
fda
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
<p align="justify">REHOVOT, Israel and HOBOKEN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biophar
Mar 11, 2026
earnings
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
<p align="justify">REHOVOT, Israel, and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopha
Mar 11, 2026
dividend
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
Company Reports Record Revenue and Profitability for Full-Year 2025 <pre>Company Reports Record Revenue and Profitability for Full-Year 2025</pre>
Mar 11, 2026
earnings_calendar
KMDA Q4 2025 Earnings Before Market Open — 2026-03-11